Orchid Pharma Limited — Others, 12-02-2025: Statement of deviation(s) or variation(s) under Reg. 32

Orchid Pharma Limited has announced a board meeting to review the financial results for the quarter and half-year ended December 31, 2024. The board approved the unaudited financial results, which indicate a total outstanding bank loan of ₹73.44 crore, with no current defaults reported. Additionally, the company provided statements regarding deviations and its debt securities, underscoring operational transparency.

The emphasis on maintaining financial discipline could foster investor confidence, suggesting a positive outlook as the company navigates its recovery efforts and potential restructuring strategies. However, ongoing discussions regarding leased properties underline an area of risk that investors should monitor closely.